High risk HPV testing for cervical cancer screening in a Puerto Rican population.

Gynecol Oncol Rep

CorePlus Servicios Clínicos y Patológicos LLC, Carolina, PR 00983, United States.

Published: August 2023

The Human Papillomavirus (HPV) causes cervical cancer, the fourth most common cause of death in women in the United States (US). Several major screening clinical trials have demonstrated that high risk HPV (HR-HPV) DNA primary screen is more sensitive at determining the risk of cervical intraepithelial neoplasia level 3 or higher (CIN ≥ 3) than cytology alone and is similar to co-testing. In this cross-sectional study, we characterized a Hispanic population of 18,052 women ages 21-70 years with HR-HPV DNA testing and cytology to determine the prevalence of HR-HPV in the population and determine the likelihood of high grade squamous intraepithelial lesion (HSIL). We also compared cytology, HR-HPV DNA testing, and co-testing strategies to determine sensitivity, specificity, positive predictive value, and negative predictive value for HSIL in cervical biopsies. Results show that HR-HPV had a slightly higher sensitivity (94.2% vs 92.3%) compared to cytology for all high-grade disease (CIN2/3).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422122PMC
http://dx.doi.org/10.1016/j.gore.2023.101236DOI Listing

Publication Analysis

Top Keywords

hr-hpv dna
12
high risk
8
risk hpv
8
cervical cancer
8
dna testing
8
compared cytology
8
hr-hpv
5
hpv testing
4
cervical
4
testing cervical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!